Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma reports net...

    Sun Pharma reports net profit of Rs 1064 crore in Q2

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-10T09:30:48+05:30  |  Updated On 10 Nov 2019 9:30 AM IST
    Sun Pharma reports net profit of Rs 1064 crore in Q2

    Total revenue from operations during the period under review stood at Rs 8,123.35 crore as against Rs 6,937.63 crore in the year-ago quarter, said Sun Pharma.


    New Delhi: Shares of Sun Pharmaceutical Industries on Thursday went up by over 3 per cent after the company reported a consolidated net profit at Rs 1,064.09 crore in the second quarter ended September 30. The company's scrip climbed 3.02 per cent to close at Rs 440.45 on the BSE. During the trade, it jumped 3.84 per cent to Rs 444.


    It was the top gainer among the 30-Sensex components. On the NSE, it gained 3.41 per cent to close at Rs 442.50.


    In terms of the traded volume, 8.96 lakh shares of the company were traded on the BSE and over one crore shares on the NSE during the day.


    Read Also: Sun Pharma signs licensing pact with AstraZeneca to introduce Novel Oncology products in China


    The company had posted a consolidated net loss of Rs 269.6 crore in the same period last fiscal, Sun Pharma said in a regulatory filing.


    Total revenue from operations during the period under review stood at Rs 8,123.35 crore as against Rs 6,937.63 crore in the year-ago quarter, it added.


    Sun Pharma said its active pharmaceutical ingredients (API) clocked external sales of Rs 468 crore, up 10 per cent over the same quarter last fiscal.


    Read Also: Sun Pharma Advanced Research Company Q2 loss widens to Rs 63 cr

    active pharmaceutical ingredientsAPIBSENSESun PharmaSun pharma financial resultssun pharma profitSun Pharma Q2sun pharma september quarter
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok